Last reviewed · How we verify
E. coli ETVAX — Competitive Intelligence Brief
phase 2
Infectious Diseases
Biologic
Live · refreshed every 30 min
Target snapshot
E. coli ETVAX (E. coli ETVAX) — Scandinavian Biopharma AB. ETVAX is a vaccine that stimulates the immune system to produce antibodies against E. coli.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| E. coli ETVAX TARGET | E. coli ETVAX | Scandinavian Biopharma AB | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- E. coli ETVAX CI watch — RSS
- E. coli ETVAX CI watch — Atom
- E. coli ETVAX CI watch — JSON
- E. coli ETVAX alone — RSS
Cite this brief
Drug Landscape (2026). E. coli ETVAX — Competitive Intelligence Brief. https://druglandscape.com/ci/e-coli-etvax. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing